ClinicalTrials.gg
Not yet recruitingNCT06387420Updated Apr 29, 2024

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

A Phase 1/2 interventional study of AK117 and Azacitidine in ACUTE MYELOID LEUKEMIA; AML, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
64th of 433
180 · median 50
Started
2024
with 67 others
Phase 1/2
66 of 473
39 open now
Primary completion
2026-04
later than 102 of 288 live
Registered
309th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 64th largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 66 in phase 1/2, reaches primary completion later than 102 of the 288 other live ones, and was the 309th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML.

03

Conditions studied

  • ACUTE MYELOID LEUKEMIA; AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old at the time of enrolment.
  • Has an (ECOG) performance status of 0\~3, and 0\~2 are required for subjects ≥75 years old.
  • Has a of at least 12 weeks.
  • Diagnosed as AML diagnosed according to WHO 2022 criteria.
  • Has adequate organ function.
  • All female and male subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with acute promyelocytic leukemia, BCR-ABL1-positive AML, myeloid sarcoma, mixed phenotype acute leukemia (MPAL), accelerated phase or blast crisis of Chronic Myeloid Leukemia.
  • has central nervous system leukemia (CNSL).
  • Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 6, 2023 for AML.
  • Previously diagnosed with another or have any evidence of residual disease.
  • Previous hematopoietic stem cell transplant (allo-HSCT).
  • Prior treatment with any B-cell lymphoma 2 (Bcl-2) inhibitors, anti-7 or anti-SIRPα (signal regulatory protein alpha) agent.
  • Use strong or moderate cytochrome P450 (CYP) 3A inducers systemically within one week prior to enrollment, or currently require long-term treatment with a moderate to strong inducer.
  • Previously diagnosed with MDS and treated with demethylating drugs.
  • Patients with known cardiopulmonary disease defined as unstable angina, arrhythmia, congestive heart failure ( Class III or IV), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders.
  • Other conditions where the investigator considers the patient inappropriate for enrollment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    AK117+Azacitidine+Venetoclax

    Phase Ib: Subjects will receive: A117: different doses on every 2 weeks, azacitidine: 75 mg/m\^2 on Days 1-7 each cycle, venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter; Phase II: Subjects will receive: AK117: the recommended Phase 2 dose (RP2D) on every two weeks, azacitidine: 75 mg/m\^2 on Days 1-7 each cycle, venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter.

    Drug: AK117 · Drug: Azacitidine · Drug: Venetoclax

  • Placebo comparator
    Placebo+Azacitidine+Venetoclax

    Phase II: Subjects will receive: placebo: the recommended Phase 2 dose (RP2D) on every two weeks, azacitidine: 75 mg/m\^2 on Days 1-7 each cycle, venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter.

    Drug: Azacitidine · Drug: Venetoclax · Other: Placebo

Interventions

  • DrugAK117

    Subjects receive AK117 intravenously.

  • Subjects receive azacitidine subcutaneously.

  • Subjects receive venetoclax orally.

  • OtherPlacebo

    Subjects receive placebo intravenously.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of participants with dose limiting toxicity (DLT)

    Any untoward medical occurrence in a subject within the first cycle, considered related to the study treatment

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Phase 1b/2: Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: Up to approximately 2 years.

  3. Phase 1b/2: Composite complete remission rate (CCR)

    The proportion of subjects achieving complete remission (CR) , complete remission with partial hematologic recovery (CRh) or complete remission with incomplete hematologic recovery (CRi) per European LeukemiaNet (ELN) 2022 criteria

    Time frame: Time Frame: Up to approximately 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    The proportion of subjects with recorded response per European LeukemiaNet (ELN) 2022

    Time frame: Up to approximately 2 years

  2. Time to response (TTR)

    Time from cycle 1 day 1(C1D1) to the first recorded response

    Time frame: Up to approximately 2 years

  3. Time to CCR (TTCCR)

    Time from C1D1 to the first recorded CR, CRh or CRi

    Time frame: Up to approximately 2 years

  4. Duration of response (DoR)

    Time from the first recorded response until disease progression, relapse, or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  5. Duration of CCR (DoCCR)

    Time from the first recorded CR, CRh or CRi until disease progression, relapse, or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  6. Rate of CCR Without Minimal Residual Disease (CCR MRD-)

    The proportion of subjects achieving CR, CRh or CRi with MRD-negative status per ELN 2022 criteria.

    Time frame: Up to approximately 2 years

  7. Event-free survival (EFS)

    Time from C1D1 until disease progression, relapse, or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  8. Overall survival (OS)

    Up to approximately 2 years

    Time frame: The time from C1D1 until death due to any cause

  9. Peak of Serum Concentration (Cmax)

    Maximal serum concentrations of AK117 in individual subjects at different time points after AK117 administration

    Time frame: Up to approximately 2 years

  10. Anti-drug antibody (ADA)

    Number of subjects with detectable anti-drug antibodies

    Time frame: Up to approximately 2 years

  11. Receptor occupancy (RO)

    CD47 occupancy rate on peripheral blood T cells and red blood cells before and after AK117 administration

    Time frame: Up to approximately 2 years

07

Study locations

1 site
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Tianjin, China
    • Jianxiang Wang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Apr 2026, 24 months later.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 24 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
Apr 29, 2024
StartEst.
Apr 29, 2024
Primary completionEst.
Apr 2026
CompletionEst.
Apr 2027
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06387420
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Apr 29, 2024 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 29, 2024

Study contacts

Jie Yang, MD
Contact
jie.yang@akdsobio.com
+86(0760)89873999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ligufalimab

Start the discussion